本文選題：血小板聚集率 + CYPC基因多態(tài)性��； 參考：《中國動脈硬化雜志》2017年05期

【摘要】：目的探討經(jīng)皮冠狀動脈介入(PCI)術(shù)后患者血小板聚集功能的影響因素。方法 266例冠心病行PCI的患者,均予以氯吡格雷和阿司匹林雙聯(lián)抗血小板及冠心病標(biāo)準(zhǔn)治療,根據(jù)術(shù)后血小板聚集率(PAR)分為0%~29%、30%~49%、50%~69%、70%~100%等4組,比較4組患者的CYP2C19基因型、一般臨床信息、冠狀動脈病變情況及生化指標(biāo),并通過Logistic回歸分析,找出PAR升高的危險因素。結(jié)果患者的性別構(gòu)成比、年齡、腦鈉肽(BNP)、CYP2C19基因型在不同PAR分組間存在差異(P0.05)。Logistic回歸分析顯示,PAR升高≥50%的危險因素是女性(OR=2.713,P=0.027)、高BNP(OR=1.002,P=0.007)、CYP2C19呈慢代謝型(OR=5.159,P0.001);PAR升高≥70%的獨(dú)立危險因素是女性(OR=5.716,P=0.008)、CYP2C19呈慢代謝型(OR=3.149,P=0.049)。結(jié)論 PAR50%的患者以CYP2C19快代謝基因型為主,而慢代謝基因型的患者PAR多為50%以上,CYP2C19基因多態(tài)性對PAR影響顯著。另外,女性、高BNP可能是冠心病患者PCI術(shù)后PAR升高的危險因素。
[Abstract]:Objective to investigate the influencing factors of platelet aggregation after percutaneous coronary intervention (PCI). Methods 266 patients who underwent PCI were treated with clopidogrel and aspirin combined anti-platelet therapy and coronary heart disease standard. According to the postoperative platelet aggregation rate (par), the patients were divided into 4 groups, including 50, 29g, 30g, 49g, 50g, 6949g, 70,70,100%, etc. The genotypes of CYP2C19 were compared among the 4 groups. General clinical information, coronary artery disease and biochemical indexes were analyzed. Logistic regression analysis was used to find out the risk factors of par elevation. Results the sex composition ratio, age of the patients, There were significant differences in CYP2C19 genotypes among different par groups (P0.05). Logistic regression analysis showed that the risk factors of increased par 鈮，

本文編號：2061944